Four HER2 + breast cancer cell lines were tested, of which two were responsive to trastuzumab and lapatinib (SKBR3 and BT-474) and two were poorly responding (SUM190PT and KPL4)20. This evidence concerns the gene ERBB2 and breast carcinoma.